v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | ACTRN12622000386730 |
Full text link
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
First author
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Contact
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
info@PACTrial.com.au |
Registration date
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
2022-03-04 |
Recruitment status
Last imported at : June 2, 2022, 8 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Recruiting |
Study design
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
RCT |
Allocation
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Randomized |
Design
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Parallel |
Masking
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Blind label |
Center
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
multi-center |
Study aim
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Treatment |
Inclusion criteria
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
• COVID-19 diagnosis in the preceding 4 days (RAT positive or PCR positive) • At least 40 years old |
Exclusion criteria
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
• Women who are pregnant, breastfeeding or actively trying to achieve a pregnancy • Current hospital inpatient with COVID-19 related disease • Allergy to ivermectin, doxycycline or famotidine • Known bleeding disorder • Known severe liver disease • Diagnosis of Myasthenia Gravis/SLE • Consumption of grapefruit juice • Ever travelled to countries that are endemic for Loa loa (West and Central Africa – Angola, Cameroon, Central African Republic, Democratic Republic of Congo, Ethiopia, Guinea, Gabon, Republic of Congo, Nigeria and Sudan) • Currently on the following medications: o Cardiac - quinidine, amiodarone, diltiazem, verapamil, warfarin o Anti-infective – clarithromycin, erythromycin, itraconazole, ketoconazole, o Anti-viral – indinavir, ritonavir, cobicistat o Disease modifying – cyclosporine, tacrolimus, sirolimus, methotrexate o Other – retinoids, lithium, spironlactone Neither minority groups nor NESB/LOTE persons will be excluded provided they possess the capacity (ie ability to understand, retain, comprehend and dutifully consider a response) to consent. |
Number of arms
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
2 |
Funding
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
AProf Dr Karin Ried |
Inclusion age min
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
40 |
Inclusion age max
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
100 |
Countries
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Australia |
Type of patients
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Mild disease at enrollment |
Severity scale
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
1: Mild disease at enrollment |
Total sample size
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
300 |
primary outcome
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
The primary outcome of this trial is hospital admission.Hospital admission is defined as the requirement to receive inpatient care for a COVID-19 related illness.This can include short stay emergency department admission; hospital in the home (HITH) admission/care; general medical admission; intensive care admission.Assessed by data linkage to patient medical records[daily for 15 days since enrolment] |
Notes
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Phase
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Phase 1/Phase 2 |
Arms
Last imported at : March 11, 2022, 3:30 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
[{"arm_notes": "", "treatment_id": 2404, "treatment_name": "Doxycycline+famotidine+ivermectin+vitamin c+vitamin d+zinc", "treatment_type": "Antibiotics+others pharmacological treatment+antiparasitics+vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2403, "treatment_name": "Doxycycline+ivermectin+vitamin c+vitamin d+zinc", "treatment_type": "Antibiotics+antiparasitics+vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}] |